Pharmacological modulation in mesial temporal lobe epilepsy: Current status and future perspectives

Antonio Gambardella, Angelo Labate, Pierangelo Cifelli, Gabriele Ruffolo, Laura Mumoli, Eleonora Aronica, Eleonora Palma

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Mesial temporal lobe epilepsy (MTLE) is frequently associated with hippocampal sclerosis (Hs), possibly caused by a primary brain injury that occurs a long time before the appearance of neurological symptoms. MTLE-Hs is, however, a heterogeneous condition that evolves with time, involving both environmental and genetic components. Recent experimental studies emphasize that drugs or drug combinations that target modulation and circuitry reorganization of the epileptogenic networks favorably modify the complex molecular and cellular alterations underlying MTLE. In particular, the link between neuroinflammation, GABAAR and epilepsy has been extensively studied mainly because of the relevant therapeutic implications that the pharmacological modulation of these phenomena would have in the clinical practice. In this review, we briefly summarize the studies that could pave the road to develop new disease-modifying therapeutic strategies for pharmacoresistant MTLE patients. Both clinical observations in human MTLE and experimental findings will be discussed, highlighting the potential modulatory crosstalk between the deregulation of the inhibitory (GABAergic) transmission and the sustained activation of the innate immune response.

Original languageEnglish
Pages (from-to)421-425
Number of pages5
JournalPharmacological Research
Volume113
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Temporal Lobe Epilepsy
Pharmacology
Sclerosis
Drug Combinations
Innate Immunity
Brain Injuries
Epilepsy
Therapeutics
Pharmaceutical Preparations

Keywords

  • AEDs
  • GABA
  • Hippocampal sclerosis
  • MTLE
  • Neuroinflammation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacological modulation in mesial temporal lobe epilepsy : Current status and future perspectives. / Gambardella, Antonio; Labate, Angelo; Cifelli, Pierangelo; Ruffolo, Gabriele; Mumoli, Laura; Aronica, Eleonora; Palma, Eleonora.

In: Pharmacological Research, Vol. 113, 01.11.2016, p. 421-425.

Research output: Contribution to journalArticle

Gambardella, Antonio ; Labate, Angelo ; Cifelli, Pierangelo ; Ruffolo, Gabriele ; Mumoli, Laura ; Aronica, Eleonora ; Palma, Eleonora. / Pharmacological modulation in mesial temporal lobe epilepsy : Current status and future perspectives. In: Pharmacological Research. 2016 ; Vol. 113. pp. 421-425.
@article{90bc09b3b8134f8b8aa6664ec764b455,
title = "Pharmacological modulation in mesial temporal lobe epilepsy: Current status and future perspectives",
abstract = "Mesial temporal lobe epilepsy (MTLE) is frequently associated with hippocampal sclerosis (Hs), possibly caused by a primary brain injury that occurs a long time before the appearance of neurological symptoms. MTLE-Hs is, however, a heterogeneous condition that evolves with time, involving both environmental and genetic components. Recent experimental studies emphasize that drugs or drug combinations that target modulation and circuitry reorganization of the epileptogenic networks favorably modify the complex molecular and cellular alterations underlying MTLE. In particular, the link between neuroinflammation, GABAAR and epilepsy has been extensively studied mainly because of the relevant therapeutic implications that the pharmacological modulation of these phenomena would have in the clinical practice. In this review, we briefly summarize the studies that could pave the road to develop new disease-modifying therapeutic strategies for pharmacoresistant MTLE patients. Both clinical observations in human MTLE and experimental findings will be discussed, highlighting the potential modulatory crosstalk between the deregulation of the inhibitory (GABAergic) transmission and the sustained activation of the innate immune response.",
keywords = "AEDs, GABA, Hippocampal sclerosis, MTLE, Neuroinflammation",
author = "Antonio Gambardella and Angelo Labate and Pierangelo Cifelli and Gabriele Ruffolo and Laura Mumoli and Eleonora Aronica and Eleonora Palma",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.phrs.2016.09.019",
language = "English",
volume = "113",
pages = "421--425",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Pharmacological modulation in mesial temporal lobe epilepsy

T2 - Current status and future perspectives

AU - Gambardella, Antonio

AU - Labate, Angelo

AU - Cifelli, Pierangelo

AU - Ruffolo, Gabriele

AU - Mumoli, Laura

AU - Aronica, Eleonora

AU - Palma, Eleonora

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Mesial temporal lobe epilepsy (MTLE) is frequently associated with hippocampal sclerosis (Hs), possibly caused by a primary brain injury that occurs a long time before the appearance of neurological symptoms. MTLE-Hs is, however, a heterogeneous condition that evolves with time, involving both environmental and genetic components. Recent experimental studies emphasize that drugs or drug combinations that target modulation and circuitry reorganization of the epileptogenic networks favorably modify the complex molecular and cellular alterations underlying MTLE. In particular, the link between neuroinflammation, GABAAR and epilepsy has been extensively studied mainly because of the relevant therapeutic implications that the pharmacological modulation of these phenomena would have in the clinical practice. In this review, we briefly summarize the studies that could pave the road to develop new disease-modifying therapeutic strategies for pharmacoresistant MTLE patients. Both clinical observations in human MTLE and experimental findings will be discussed, highlighting the potential modulatory crosstalk between the deregulation of the inhibitory (GABAergic) transmission and the sustained activation of the innate immune response.

AB - Mesial temporal lobe epilepsy (MTLE) is frequently associated with hippocampal sclerosis (Hs), possibly caused by a primary brain injury that occurs a long time before the appearance of neurological symptoms. MTLE-Hs is, however, a heterogeneous condition that evolves with time, involving both environmental and genetic components. Recent experimental studies emphasize that drugs or drug combinations that target modulation and circuitry reorganization of the epileptogenic networks favorably modify the complex molecular and cellular alterations underlying MTLE. In particular, the link between neuroinflammation, GABAAR and epilepsy has been extensively studied mainly because of the relevant therapeutic implications that the pharmacological modulation of these phenomena would have in the clinical practice. In this review, we briefly summarize the studies that could pave the road to develop new disease-modifying therapeutic strategies for pharmacoresistant MTLE patients. Both clinical observations in human MTLE and experimental findings will be discussed, highlighting the potential modulatory crosstalk between the deregulation of the inhibitory (GABAergic) transmission and the sustained activation of the innate immune response.

KW - AEDs

KW - GABA

KW - Hippocampal sclerosis

KW - MTLE

KW - Neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=84988526089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988526089&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2016.09.019

DO - 10.1016/j.phrs.2016.09.019

M3 - Article

AN - SCOPUS:84988526089

VL - 113

SP - 421

EP - 425

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -